44 completed, 13 terminated, 3 recruiting, 1 suspended. 62 Phase 1, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 62 | Completed 44, Terminated 13, Recruiting 3, Suspended 1, Unknown 1 |
| Phase 2 | 11 | Terminated 6, Completed 4, Unknown 1 |
Follow Neoplasm: new trials by email Literature Review of Neoplasm trials Research Report on Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intratumoral Macrophage Exosomes With Mechanobiological Reprogramming for Advanced Solid Tumors Mechanobiologically Reprogrammed Macrophage-Derived Exosomes (1×10^10 exosomes), Mechanobiologically Reprogrammed Macrophage-Derived Exosomes (2.5×10^10 exosomes), Mechanobiologically Reprogrammed Macrophage-Derived Exosomes (5×10^10 exosomes) - Advanced Solid Tumors, Neoplasm | Phase 1 | Recruiting | West China Hospital | 9 | 2026-05-10 | 2026-05-11 |
| Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib [14C] AZD6738, AZD6738 / ceralasertib - Neoplasm | Phase 1 | Terminated | AstraZeneca | 2 | 2025-09-22 | 2026-09-03 |
| A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma KLN-1010 - Multiple Myeloma in Relapse, Myeloma Multiple | Phase 1 | Recruiting | Kelonia Therapeutics, Inc. | 70 | 2025-07-16 | 2026-08-28 |
| A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies COM503, Zimberelimab - Neoplasm, Cancer, Malignant Tumors | Phase 1 | Recruiting | Compugen Ltd | 200 | 2025-01-07 | 2026-08-12 |
| Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors Tusamitamab ravtansine - Neoplasm | Phase 1 | Terminated | Sanofi | 56 | 2022-10-03 | 2025-04-06 |
| Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors SAR444200, Atezolizumab - Neoplasm | Phase 1 / Phase 2 | Terminated | Sanofi | 33 | 2022-09-20 | 2026-01-14 |
| Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors SAR443216 IV, SAR443216 SC - Neoplasm Malignant, Breast Cancer | Phase 1 | Terminated | Sanofi | 44 | 2021-08-16 | 2025-09-15 |
| Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors SAR444881, Pembrolizumab, Cetuximab - Cancer, Neoplasm | Phase 1 / Phase 2 | Terminated | Sanofi | 125 | 2021-04-11 | 2026-09-29 |
| A Study to Test Different Doses of BI 891065 Alone and in Combination With BI 754091 in Asian Patients With Different Types of Advanced Cancer (Solid Tumours) BI 891065 - Neoplasm | Phase 1 | Completed | Boehringer Ingelheim | 12 | 2019-11-26 | 2024-10-09 |
| A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers JNJ-63723283, Erdafitinib - Neoplasm | Phase 1 | Completed | Janssen Pharmaceutical K.K. | 22 | 2018-08-31 | 2025-04-28 |
| Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies Isatuximab SAR650984, Atezolizumab - Neoplasm | Phase 1 / Phase 2 | Terminated | Sanofi | 107 | 2018-08-06 | 2023-07-10 |
| A Study of ASN007 in Patients With Advanced Solid Tumors ASN007: ascending doses, ASN007 RD - Cancer, Malignancy | Phase 1 | Completed | Asana BioSciences | 49 | 2018-01-19 | 2020-07-09 |
| A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors BMS-986226, Nivolumab, Ipilimumab - Cancer, Tumors | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 80 | 2017-09-01 | 2023-02-28 |
| Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062) preladenant, pembrolizumab - Neoplasm | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 10 | 2017-06-27 | 2019-06-05 |
| A Phase I Trial of HS-10241 in Solid Tumors HS-10241 - Neoplasm, Solid Tumors | Phase 1 | Completed | Atridia Pty Ltd. | 7 | 2016-09-01 | 2022-07-20 |
| A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer SHR3680; SHR3162 - Neoplasm, Prostate Cancer | Phase 1 | Completed | Atridia Pty Ltd. | 33 | 2016-09-01 | 2020-07-21 |
| A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors SHR3162 - Neoplasm, Solid Tumors | Phase 1 | Completed | Atridia Pty Ltd. | 30 | 2016-06-01 | 2019-09-19 |
| A Study of SHR6390 in Advanced Solid Tumor Patients SHR6390 - Neoplasm | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 40 | 2016-03-03 | 2022-07-11 |
| A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors SDX-7320 - Advanced Malignancy, Advanced Solid Tumors | Phase 1 | Completed | SynDevRx, Inc. | 32 | 2016-02-01 | 2020-01-27 |
| A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers Prexasertib - Neoplasm | Phase 1 | Completed | Eli Lilly and Company | 12 | 2015-10-01 | 2017-05-22 |
Showing 20 of 62. Sign in to see all of them.
Neoplasms (62) · Neoplasm Metastasis (12) · Lymphoma (4) · Melanoma (4) · Breast Neoplasms (2) · Carcinoma, Hepatocellular (2) · Lung Neoplasms (2) · Lymphoma, B-Cell (2) · Lymphoma, Follicular (2) · Prostatic Neoplasms (2) · Agnosia (1) · Blood Protein Disorders (1) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1)
Pathological Conditions, Signs and Symptoms (16) · Pathologic Processes (14) · Neoplasms by Site (13) · Neoplastic Processes (12) · Neoplasms by Histologic Type (11) · Hemic and Lymphatic Diseases (7) · Skin Diseases (7) · Skin and Connective Tissue Diseases (7) · Lymphatic Diseases (6) · Digestive System Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphoproliferative Disorders (5) · Digestive System Neoplasms (4) · Male Urogenital Diseases (4)
BCT-100 (2) · Doxorubicin (2) · P276-00 (2) · Pemetrexed (2) · Radiotherapy (2) · atezolizumab (2) · fluzoparib (2) · pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1) · 2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7H-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine (1) · 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one (1) · 5H-benzo(4,5)cyclohepta(1,2-b)pyridin-5-one (1) · 7-hydroxystaurosporine (1) · ADI PEG20 (1) · Albumin-Bound Paclitaxel (1)
National Cancer Institute (NCI) (8) · Eli Lilly and Company (5) · Sanofi (5) · Merck Sharp & Dohme LLC (4) · Atridia Pty Ltd. (3) · SynerGene Therapeutics, Inc. (3) · Asana BioSciences (2) · Bayer (2) · Bio-Cancer Treatment International Limited (2) · INSYS Therapeutics Inc (2) · Ludwig Institute for Cancer Research (2) · Pfizer (2) · Piramal Enterprises Limited (2) · AstraZeneca (1) · Boehringer Ingelheim (1)
United States (40) · Canada (8) · Spain (6) · United Kingdom (6) · Japan (5) · Australia (4) · Belgium (3) · China (3) · France (3) · Germany (3) · Israel (3) · Italy (3) · Hong Kong (2) · India (2) · Netherlands (2)
Raghunadharao D, MD, DM (2) · Ronnie TP Poon, Prof (2) · Alice P Chen, M.D. (1) · Anna Pavlick, DO (1) · Arlene Siefker-Radtke, M.D. (1) · Binhe Xu, M.D (1) · Bryan Leigh, MD (1)
PMID 19238148, PMID 19728336, PMID 20955619, PMID 22143378, PMID 22570147, PMID 22864522, PMID 23054206, PMID 24919854, PMID 31401903, PMID 32554315, PMID 33845905, PMID 33856599, PMID 36096532, PMID 36335217, PMID 36813886, PMID 37219686, PMID 41408891, PMID 42705861
2023 (2), 2008 (1), 2017 (1), 2018 (1)